KDR and neoplasm: On the contrary, Anlotinib is a novel small molecule, a multi-target tyrosine kinase inhibitor that effectively inhibits VEGFR, PDGFR, FGFR, c-Kit, and other kinases, and has anti-tumor angiogenic effects.